Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...
This bill comes after the state Division of Public Health said it must reduce select services for residents with HIV due to ...
The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences’ twice-yearly HIV pre-exposure prophylaxis (PrEP) med Yeztugo, ...
Alexis Perkins thought her OB-GYN's office in Atlanta would be just the place to get a prescription for the type of drug that reduces a person's risk of contracting HIV. But during a recent visit, the ...
Partnering with Gilead, Ciara is using her music to encourage education, protection, and broader conversations around PrEP & ...
A little specificity would go a long way in the recommendations of the US Preventive Services Task Force (USPSTF)—that is, if we want health insurance companies to pay for lifesaving HIV prevention ...
Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE ...
Nationwide, an estimated 1.2 million people are eligible to receive medication that can prevent the spread of life-threatening HIV infection. But only roughly a third of those eligible are currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results